Evommune, Inc.(EVMN)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNYS
- Market Cap
- $0.7B
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +4.50% | 1 |
| Feb | +40.46% | 1 |
| Mar | -10.23% | 1 |
| Apr | +3.48% | 1 |
| May | -4.91% | 1 |
| Jun | -14.64% | 1 |
| Jul | — | 0 |
| Aug | — | 0 |
| Sep | — | 0 |
| Oct | — | 0 |
| Nov | -0.58% | 1 |
| Dec | -25.01% | 1 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
- Beta (1Y vs SPY)
- 1.51
- Correlation (SPY)
- 15.9%
- R²
- 0.03
- Ann. Volatility
- 128.3%
- SPY Volatility
- 13.5%
High volatility - stock moves more than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | ARTHUR S KIRSCH | Director | Grant (A) | +15,673 opt | — | EDGAR | |
| 2026-06-03 | Jeegar Pravinkumar Patel | Chief Scientific Officer | Mixed | −3,175 | $14.28 | -$327.6K | EDGAR |
| 2026-06-03 | Luis C. Pena | President & CEO | Sell (S) | −16,787 | $22.74 | -$381.7K | EDGAR |
| 2026-06-03 | David E Cohen | Director | Sell (S) | −6,056 | $20.33 | -$123.1K | EDGAR |
| 2026-06-03 | BENJAMIN F III MCGRAW | Director | Grant (A) | +15,673 opt | — | EDGAR | |
| 2026-06-01 | Kyle Carver | Chief Financial Officer | Mixed | −3,175 | $13.86 | -$370.3K | EDGAR |
| 2026-06-01 | Gregory S. Moss | Chief Business & Legal Officer | Mixed | — | $12.27 | -$300.4K | EDGAR |
| 2026-04-17 | Janice Suzann Drew | Chief of Dev. Operations | Grant (A) | +73,892 opt | — | EDGAR | |
| 2026-04-17 | Luis C. Pena | President & CEO | Grant (A) | +291,420 opt | — | EDGAR | |
| 2026-04-17 | Eugene Bauer | Chief Medical Officer | Grant (A) | +51,117 opt | — | EDGAR | |
| 2026-04-17 | Gregory S. Moss | Chief Business & Legal Officer | Grant (A) | +115,279 opt | — | EDGAR | |
| 2026-04-17 | Jeegar Pravinkumar Patel | Chief Scientific Officer | Grant (A) | +69,315 opt | — | EDGAR | |
| 2026-04-17 | Kyle Carver | Chief Financial Officer | Grant (A) | +98,946 opt | — | EDGAR | |
| 2026-02-19 | 7 Cooperative UA LSP | Director | Award (A) | +358,680 | $27.88 | $10.00M | EDGAR |
| 2026-02-18 | Weegen Felice Isabel Verduyn-van | Director | Award (A) | +358,680 | $27.88 | $10.00M | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | 7 Cooperative UA LSP | Director | 5,288,313 | $104.87M | $0 | 1 | 2026-02-19 |
| 2 | Weegen Felice Isabel Verduyn-van | Director | 5,288,313 | $104.87M | $0 | 1 | 2026-02-18 |
| 3 | RA Capital Nexus Fund III, L.P. | Director | 2,710,293 | $53.75M | $0 | 1 | 2026-02-17 |
| 4 | Luis C. Pena | President & CEO | 637,896 | $12.65M | -$381.7K | 3 | 2026-06-03 |
| 5 | Robert Lorne Hopfner | Director | 294,502 | $5.84M | $17.4K | 1 | 2025-12-22 |
| 6 | Eugene Bauer | Chief Medical Officer | 270,818 | $5.37M | $0 | 3 | 2026-04-17 |
| 7 | Kyle Carver | Chief Financial Officer | 77,510 | $1.54M | -$415.1K | 3 | 2026-06-01 |
| 8 | Janice Suzann Drew | Chief of Dev. Operations | 67,794 | $1.34M | $0 | 2 | 2026-04-17 |
| 9 | Gregory S. Moss | Chief Business & Legal Officer | 64,010 | $1.27M | -$324.7K | 3 | 2026-06-01 |
| 10 | Jeegar Pravinkumar Patel | Chief Scientific Officer | 63,090 | $1.25M | -$379.5K | 3 | 2026-06-03 |
| 11 | David E Cohen | Director | 18,209 | $361.1K | -$123.1K | 1 | 2026-06-03 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.